Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Net Income (2016 - 2025)

Historic Net Income for Ligand Pharmaceuticals (LGNYZ) over the last 13 years, with Q3 2025 value amounting to $117.3 million.

  • Ligand Pharmaceuticals' Net Income changed N/A to $117.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year change of. This contributed to the annual value of -$4.0 million for FY2024, which is 14216.22% down from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Net Income is $117.3 million.
  • Over the past 5 years, Ligand Pharmaceuticals' Net Income peaked at $117.3 million during Q3 2025, and registered a low of -$42.5 million during Q1 2025.
  • For the 5-year period, Ligand Pharmaceuticals' Net Income averaged around -$33923.1, with its median value being -$4.7 million (2021).
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Net Income soared by 8068.87% in 2021, and later tumbled by 13603.29% in 2022.
  • Over the past 5 years, Ligand Pharmaceuticals' Net Income (Quarter) stood at -$2.2 million in 2021, then tumbled by 32.75% to -$3.0 million in 2022, then skyrocketed by 43.58% to -$1.7 million in 2023, then crashed by 1767.15% to -$31.1 million in 2024, then surged by 477.23% to $117.3 million in 2025.
  • Its last three reported values are $117.3 million in Q3 2025, $4.8 million for Q2 2025, and -$42.5 million during Q1 2025.